# Determine the Pharmacokinetics and Safety of Brivanib in Chinese Subjects With Advanced Primary Liver Cancer (Hepatocellular Carcinoma: HCC)

> **NCT01540461** · PHASE1 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 17 (actual)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Brivanib

## Key facts

- **NCT ID:** NCT01540461
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-03
- **Primary completion:** 2013-11
- **Final completion:** 2013-11
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2014-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01540461

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01540461, "Determine the Pharmacokinetics and Safety of Brivanib in Chinese Subjects With Advanced Primary Liver Cancer (Hepatocellular Carcinoma: HCC)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01540461. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*